chrisdorney / Shutterstock.com

15 July 2021Europe

CMA fines drugmakers £260m for 10,000% price hike

The UK’s Competition and Markets Authority (CMA) has imposed fines of £260 million on drug companies for raising the price of life-saving hydrocortisone tablets by 10,000%.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

CMA accuses 4 pharma companies of anti-competitive conduct

24 May 2019 Four pharmaceutical companies allegedly agreed not to compete for the supply of an anti-nausea tablet to the National Health Service, according to objections filed by the UK Competition and Markets Authority.

CMA accuses hydrocortisone suppliers of anti-competitive behaviour

4 March 2019 The UK Competition and Markets Authority has provisionally found that pharmaceutical companies Auden Mckenzie and Waymade engaged in anti-competitive behaviour relating to hydrocortisone tablets.

More on this story

CMA accuses 4 pharma companies of anti-competitive conduct

24 May 2019 Four pharmaceutical companies allegedly agreed not to compete for the supply of an anti-nausea tablet to the National Health Service, according to objections filed by the UK Competition and Markets Authority.

CMA accuses hydrocortisone suppliers of anti-competitive behaviour

4 March 2019 The UK Competition and Markets Authority has provisionally found that pharmaceutical companies Auden Mckenzie and Waymade engaged in anti-competitive behaviour relating to hydrocortisone tablets.

More on this story

CMA accuses 4 pharma companies of anti-competitive conduct

24 May 2019 Four pharmaceutical companies allegedly agreed not to compete for the supply of an anti-nausea tablet to the National Health Service, according to objections filed by the UK Competition and Markets Authority.

CMA accuses hydrocortisone suppliers of anti-competitive behaviour

4 March 2019 The UK Competition and Markets Authority has provisionally found that pharmaceutical companies Auden Mckenzie and Waymade engaged in anti-competitive behaviour relating to hydrocortisone tablets.

More features

Gilead scores win in fake HIV drug dispute

Polsinelli grows roster with ex-corporate counsel

‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird

Sandoz wins $137.2m payout for lost profits in generic launch

Sanofi signs global rights deal to develop rare cancer therapy

Unified Patent Court visualised: Cases, divisions, and classes in charts

WBD to merge with firm to create ‘powerhouse’ practice

‘Be prepared, and don’t assume at the UPC’: Christopher Stothers